SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
Additionally, Invitae’s epilepsy panel can be combined for no additional charge with other panels or a single gene test for relevant developmental disorders where clinically appropriate, such as ...
(RTTNews) - The U.S. Food and Drug Administration granted de novo marketing authorization for Invitae's Common Hereditary Cancers Panel, an in vitro diagnostic test to help detect dozens of cancer ...
Invitae is building a platform to make genetic tests simple and accessible to a wide array of people. The Global Genetic Testing Market size is expected to reach $16.9 billion by 2025. By using a ...